PMC:7319919
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 526-534 | Body_part | denotes | tyrosine | http://purl.org/sig/ont/fma/fma82768 |
| T2 | 783-794 | Body_part | denotes | endothelium | http://purl.org/sig/ont/fma/fma63916 |
| T3 | 1293-1298 | Body_part | denotes | blood | http://purl.org/sig/ont/fma/fma9670 |
| T4 | 1309-1314 | Body_part | denotes | heart | http://purl.org/sig/ont/fma/fma7088 |
| T5 | 1508-1513 | Body_part | denotes | chest | http://purl.org/sig/ont/fma/fma9576 |
| T6 | 1585-1592 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
| T7 | 1652-1662 | Body_part | denotes | lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
| T8 | 1681-1686 | Body_part | denotes | Chest | http://purl.org/sig/ont/fma/fma9576 |
| T9 | 2353-2357 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T10 | 2405-2415 | Body_part | denotes | Neutrophil | http://purl.org/sig/ont/fma/fma62860 |
| T11 | 2463-2473 | Body_part | denotes | Lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
| T12 | 2576-2583 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
| T13 | 4010-4015 | Body_part | denotes | blood | http://purl.org/sig/ont/fma/fma9670 |
| T14 | 4127-4132 | Body_part | denotes | chest | http://purl.org/sig/ont/fma/fma9576 |
| T15 | 4291-4296 | Body_part | denotes | chest | http://purl.org/sig/ont/fma/fma9576 |
| T16 | 4433-4440 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
| T17 | 4484-4492 | Body_part | denotes | tyrosine | http://purl.org/sig/ont/fma/fma82768 |
| T18 | 4516-4524 | Body_part | denotes | platelet | http://purl.org/sig/ont/fma/fma62851 |
| T19 | 4827-4831 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
| T20 | 5040-5048 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T21 | 5067-5080 | Body_part | denotes | interleukin-6 | http://purl.org/sig/ont/fma/fma264829 |
| T22 | 5307-5312 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T23 | 5861-5865 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T24 | 5950-5955 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 783-794 | Body_part | denotes | endothelium | http://purl.obolibrary.org/obo/UBERON_0001986 |
| T2 | 1293-1298 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
| T3 | 1309-1314 | Body_part | denotes | heart | http://purl.obolibrary.org/obo/UBERON_0000948 |
| T4 | 1508-1513 | Body_part | denotes | chest | http://purl.obolibrary.org/obo/UBERON_0001443 |
| T5 | 1681-1686 | Body_part | denotes | Chest | http://purl.obolibrary.org/obo/UBERON_0001443 |
| T6 | 4010-4015 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
| T7 | 4127-4132 | Body_part | denotes | chest | http://purl.obolibrary.org/obo/UBERON_0001443 |
| T8 | 4291-4296 | Body_part | denotes | chest | http://purl.obolibrary.org/obo/UBERON_0001443 |
| T9 | 4827-4831 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 13-21 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T2 | 59-68 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
| T3 | 121-168 | Disease | denotes | severe acute respiratory syndrome coronavirus 2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T4 | 121-154 | Disease | denotes | severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T5 | 170-178 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T6 | 240-248 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T7 | 405-413 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T8 | 575-580 | Disease | denotes | tumor | http://purl.obolibrary.org/obo/MONDO_0005070 |
| T9 | 624-648 | Disease | denotes | chronic myeloid leukemia | http://purl.obolibrary.org/obo/MONDO_0011996 |
| T10 | 632-648 | Disease | denotes | myeloid leukemia | http://purl.obolibrary.org/obo/MONDO_0004643 |
| T11 | 640-648 | Disease | denotes | leukemia | http://purl.obolibrary.org/obo/MONDO_0005059 |
| T12 | 653-684 | Disease | denotes | gastrointestinal stromal tumors | http://purl.obolibrary.org/obo/MONDO_0011719 |
| T13 | 678-684 | Disease | denotes | tumors | http://purl.obolibrary.org/obo/MONDO_0005070 |
| T14 | 853-861 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T15 | 933-941 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T16 | 944-953 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T17 | 996-1004 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T18 | 1005-1014 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
| T19 | 1713-1722 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
| T20 | 1759-1767 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T21 | 3566-3585 | Disease | denotes | bacterial infection | http://purl.obolibrary.org/obo/MONDO_0005113 |
| T22 | 3576-3585 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T23 | 4445-4448 | Disease | denotes | ABL | http://purl.obolibrary.org/obo/MONDO_0008692 |
| T24 | 4577-4580 | Disease | denotes | ABL | http://purl.obolibrary.org/obo/MONDO_0008692 |
| T25 | 4821-4838 | Disease | denotes | acute lung injury | http://purl.obolibrary.org/obo/MONDO_0006502|http://purl.obolibrary.org/obo/MONDO_0015796 |
| T27 | 4832-4838 | Disease | denotes | injury | http://purl.obolibrary.org/obo/MONDO_0021178 |
| T28 | 4897-4912 | Disease | denotes | pulmonary edema | http://purl.obolibrary.org/obo/MONDO_0006932 |
| T29 | 5085-5090 | Disease | denotes | tumor | http://purl.obolibrary.org/obo/MONDO_0005070 |
| T30 | 5472-5480 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T31 | 5576-5584 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T32 | 5660-5693 | Disease | denotes | severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T33 | 5788-5796 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T34 | 6034-6042 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T35 | 6045-6054 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T36 | 6146-6154 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T37 | 6209-6217 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T38 | 6220-6229 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T39 | 6637-6645 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T40 | 6894-6902 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 23-24 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T2 | 182-185 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T3 | 193-194 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T4 | 271-272 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T5 | 298-310 | http://purl.obolibrary.org/obo/OBI_0000245 | denotes | Organization |
| T6 | 524-525 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T7 | 557-558 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T8 | 581-589 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T9 | 736-739 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T10 | 783-794 | http://purl.obolibrary.org/obo/UBERON_0001986 | denotes | endothelium |
| T11 | 881-884 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T12 | 981-982 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T13 | 1164-1165 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T14 | 1220-1223 | http://purl.obolibrary.org/obo/CLO_0001602 | denotes | a 6 |
| T15 | 1220-1223 | http://purl.obolibrary.org/obo/CLO_0001603 | denotes | a 6 |
| T16 | 1220-1223 | http://purl.obolibrary.org/obo/CLO_0050248 | denotes | a 6 |
| T17 | 1220-1223 | http://purl.obolibrary.org/obo/CLO_0052463 | denotes | a 6 |
| T18 | 1293-1298 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
| T19 | 1293-1298 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood |
| T20 | 1309-1314 | http://purl.obolibrary.org/obo/UBERON_0000948 | denotes | heart |
| T21 | 1309-1314 | http://purl.obolibrary.org/obo/UBERON_0007100 | denotes | heart |
| T22 | 1309-1314 | http://purl.obolibrary.org/obo/UBERON_0015228 | denotes | heart |
| T23 | 1309-1314 | http://www.ebi.ac.uk/efo/EFO_0000815 | denotes | heart |
| T24 | 1508-1513 | http://www.ebi.ac.uk/efo/EFO_0000965 | denotes | chest |
| T25 | 1554-1555 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T26 | 1643-1644 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T27 | 1681-1686 | http://www.ebi.ac.uk/efo/EFO_0000965 | denotes | Chest |
| T28 | 1750-1754 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
| T29 | 2353-2357 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T30 | 2842-2843 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T31 | 2990-2991 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T32 | 3081-3082 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T33 | 3976-3978 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
| T34 | 4010-4015 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
| T35 | 4010-4015 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood |
| T36 | 4016-4021 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tests |
| T37 | 4105-4106 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
| T38 | 4116-4117 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T39 | 4127-4132 | http://www.ebi.ac.uk/efo/EFO_0000965 | denotes | chest |
| T40 | 4221-4223 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
| T41 | 4238-4239 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
| T42 | 4291-4296 | http://www.ebi.ac.uk/efo/EFO_0000965 | denotes | chest |
| T43 | 4315-4317 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
| T44 | 4350-4352 | http://purl.obolibrary.org/obo/CLO_0001313 | denotes | 36 |
| T45 | 4614-4617 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T46 | 4654-4662 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T47 | 4827-4831 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
| T48 | 4827-4831 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
| T49 | 4854-4855 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T50 | 5067-5080 | http://purl.obolibrary.org/obo/PR_000001393 | denotes | interleukin-6 |
| T51 | 5085-5112 | http://purl.obolibrary.org/obo/PR_000000134 | denotes | tumor necrosis factor-alpha |
| T52 | 5152-5162 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activation |
| T53 | 5227-5228 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | B |
| T54 | 5270-5276 | http://purl.obolibrary.org/obo/NCBITaxon_33208 | denotes | animal |
| T55 | 5301-5312 | http://purl.obolibrary.org/obo/CLO_0053065 | denotes | human cells |
| T56 | 5315-5321 | http://purl.obolibrary.org/obo/CLO_0053799 | denotes | 4], [5 |
| T57 | 5340-5341 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | B |
| T58 | 5353-5354 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T59 | 5551-5552 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T60 | 5614-5617 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T61 | 5643-5651 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T62 | 5820-5824 | http://purl.obolibrary.org/obo/CLO_0053407 | denotes | ABL2 |
| T63 | 5855-5860 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T64 | 5861-5865 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T65 | 5950-5955 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T66 | 6338-6339 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T67 | 6611-6612 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T68 | 6777-6778 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 526-551 | Chemical | denotes | tyrosine kinase inhibitor | http://purl.obolibrary.org/obo/CHEBI_38637 |
| T2 | 526-534 | Chemical | denotes | tyrosine | http://purl.obolibrary.org/obo/CHEBI_18186 |
| T3 | 542-551 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T4 | 731-735 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T5 | 751-760 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T6 | 872-880 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
| T7 | 1028-1036 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
| T8 | 1093-1111 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T9 | 1122-1141 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
| T10 | 1122-1131 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T11 | 1132-1141 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T12 | 1390-1396 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
| T13 | 1585-1592 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T14 | 1603-1610 | Chemical | denotes | lactate | http://purl.obolibrary.org/obo/CHEBI_24996 |
| T15 | 1872-1883 | Chemical | denotes | ceftriaxone | http://purl.obolibrary.org/obo/CHEBI_29007 |
| T16 | 2041-2049 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
| T17 | 2079-2087 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
| T18 | 2117-2125 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
| T19 | 2303-2310 | Chemical | denotes | lactate | http://purl.obolibrary.org/obo/CHEBI_24996 |
| T20 | 2576-2583 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T21 | 2815-2821 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
| T22 | 3189-3197 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
| T23 | 3248-3257 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T24 | 3315-3319 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T25 | 3428-3436 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
| T26 | 3496-3507 | Chemical | denotes | ceftriaxone | http://purl.obolibrary.org/obo/CHEBI_29007 |
| T27 | 3640-3646 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
| T28 | 3801-3809 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
| T29 | 4433-4440 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T30 | 4445-4448 | Chemical | denotes | ABL | http://purl.obolibrary.org/obo/CHEBI_30805 |
| T31 | 4450-4458 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
| T32 | 4484-4492 | Chemical | denotes | tyrosine | http://purl.obolibrary.org/obo/CHEBI_18186 |
| T33 | 4577-4580 | Chemical | denotes | ABL | http://purl.obolibrary.org/obo/CHEBI_30805 |
| T34 | 4671-4675 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T35 | 4764-4772 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
| T36 | 4880-4884 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T37 | 5107-5112 | Chemical | denotes | alpha | http://purl.obolibrary.org/obo/CHEBI_30216 |
| T38 | 5223-5225 | Chemical | denotes | NF | http://purl.obolibrary.org/obo/CHEBI_141424|http://purl.obolibrary.org/obo/CHEBI_25573|http://purl.obolibrary.org/obo/CHEBI_1224 |
| T41 | 5336-5338 | Chemical | denotes | NF | http://purl.obolibrary.org/obo/CHEBI_141424|http://purl.obolibrary.org/obo/CHEBI_25573|http://purl.obolibrary.org/obo/CHEBI_1224 |
| T44 | 5405-5413 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
| T45 | 5605-5613 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
| T46 | 5633-5642 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T47 | 5990-5998 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
| T48 | 6109-6118 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T49 | 6138-6142 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T50 | 6256-6264 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
| T51 | 6581-6589 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
| T52 | 6844-6863 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
| T53 | 6844-6853 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T54 | 6854-6863 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T55 | 6865-6873 | Chemical | denotes | imatinib | http://purl.obolibrary.org/obo/CHEBI_45783 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2 | 0-8 | Chemical | denotes | Imatinib | MESH:D000068877 |
| 3 | 13-21 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 25 | 121-168 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | Tax:2697049 |
| 26 | 170-180 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 27 | 414-422 | Species | denotes | patients | Tax:9606 |
| 28 | 983-990 | Species | denotes | patient | Tax:9606 |
| 29 | 512-520 | Chemical | denotes | Imatinib | MESH:D000068877 |
| 30 | 872-880 | Chemical | denotes | imatinib | MESH:D000068877 |
| 31 | 1028-1036 | Chemical | denotes | imatinib | MESH:D000068877 |
| 32 | 1093-1111 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 33 | 1113-1116 | Chemical | denotes | HCQ | MESH:D006886 |
| 34 | 1122-1141 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
| 35 | 1143-1148 | Chemical | denotes | LPV/r | MESH:C558899 |
| 36 | 59-68 | Disease | denotes | pneumonia | MESH:D011014 |
| 37 | 240-248 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 38 | 405-413 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 39 | 575-580 | Disease | denotes | tumor | MESH:D009369 |
| 40 | 606-613 | Disease | denotes | cancers | MESH:D009369 |
| 41 | 632-648 | Disease | denotes | myeloid leukemia | MESH:D007951 |
| 42 | 653-684 | Disease | denotes | gastrointestinal stromal tumors | MESH:D046152 |
| 43 | 853-861 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 44 | 933-953 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
| 45 | 996-1014 | Disease | denotes | COVID-19 pneumonia | MESH:C000657245 |
| 47 | 2165-2168 | Gene | denotes | CRP | Gene:1401 |
| 50 | 2559-2562 | Gene | denotes | CRP | Gene:1401 |
| 51 | 2565-2583 | Gene | denotes | C-reactive protein | Gene:1401 |
| 65 | 1574-1592 | Gene | denotes | C-reactive protein | Gene:1401 |
| 66 | 1594-1597 | Gene | denotes | CRP | Gene:1401 |
| 67 | 1178-1183 | Species | denotes | woman | Tax:9606 |
| 68 | 1759-1769 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 69 | 1390-1396 | Chemical | denotes | oxygen | MESH:D010100 |
| 70 | 1825-1828 | Chemical | denotes | HCQ | MESH:D006886 |
| 71 | 1833-1838 | Chemical | denotes | LPV/r | MESH:C558899 |
| 72 | 1872-1883 | Chemical | denotes | ceftriaxone | MESH:D002443 |
| 73 | 1239-1244 | Disease | denotes | fever | MESH:D005334 |
| 74 | 1258-1268 | Disease | denotes | arthralgia | MESH:D018771 |
| 75 | 1270-1277 | Disease | denotes | malaise | MESH:D005221 |
| 76 | 1282-1287 | Disease | denotes | cough | MESH:D003371 |
| 77 | 1713-1722 | Disease | denotes | pneumonia | MESH:D011014 |
| 94 | 2914-2917 | Gene | denotes | CRP | Gene:1401 |
| 95 | 2704-2711 | Species | denotes | patient | Tax:9606 |
| 96 | 3836-3843 | Species | denotes | patient | Tax:9606 |
| 97 | 2815-2821 | Chemical | denotes | oxygen | MESH:D010100 |
| 98 | 3130-3133 | Chemical | denotes | HCQ | MESH:D006886 |
| 99 | 3138-3143 | Chemical | denotes | LPV/r | MESH:C558899 |
| 100 | 3189-3197 | Chemical | denotes | imatinib | MESH:D000068877 |
| 101 | 3428-3436 | Chemical | denotes | imatinib | MESH:D000068877 |
| 102 | 3496-3507 | Chemical | denotes | ceftriaxone | MESH:D002443 |
| 103 | 3640-3646 | Chemical | denotes | oxygen | MESH:D010100 |
| 104 | 3801-3809 | Chemical | denotes | imatinib | MESH:D000068877 |
| 105 | 3926-3929 | Chemical | denotes | HCQ | MESH:D006886 |
| 106 | 3934-3939 | Chemical | denotes | LPV/r | MESH:C558899 |
| 107 | 2783-2788 | Disease | denotes | fever | MESH:D005334 |
| 108 | 3566-3585 | Disease | denotes | bacterial infection | MESH:D001424 |
| 109 | 3608-3613 | Disease | denotes | fever | MESH:D005334 |
| 125 | 4441-4448 | Gene | denotes | BCR-ABL | Gene:25 |
| 126 | 5067-5080 | Gene | denotes | interleukin-6 | Gene:16193 |
| 127 | 5085-5112 | Gene | denotes | tumor necrosis factor-alpha | Gene:21926 |
| 128 | 5223-5228 | Gene | denotes | NF-κB | Gene:4790 |
| 129 | 5336-5341 | Gene | denotes | NF-κB | Gene:4790 |
| 130 | 4793-4799 | Species | denotes | Murine | Tax:10090 |
| 131 | 5301-5306 | Species | denotes | human | Tax:9606 |
| 132 | 5472-5482 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 133 | 4450-4458 | Chemical | denotes | imatinib | MESH:D000068877 |
| 134 | 4764-4772 | Chemical | denotes | imatinib | MESH:D000068877 |
| 135 | 5405-5413 | Chemical | denotes | imatinib | MESH:D000068877 |
| 136 | 4810-4816 | Disease | denotes | sepsis | MESH:D018805 |
| 137 | 4827-4838 | Disease | denotes | lung injury | MESH:D055370 |
| 138 | 4897-4912 | Disease | denotes | pulmonary edema | MESH:D011654 |
| 139 | 5576-5584 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 147 | 5731-5744 | Species | denotes | coronaviruses | Tax:11118 |
| 148 | 5788-5798 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 149 | 5926-5939 | Species | denotes | coronaviruses | Tax:11118 |
| 150 | 5605-5613 | Chemical | denotes | imatinib | MESH:D000068877 |
| 151 | 5990-5998 | Chemical | denotes | imatinib | MESH:D000068877 |
| 152 | 6034-6054 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
| 153 | 6146-6154 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 158 | 6256-6264 | Chemical | denotes | imatinib | MESH:D000068877 |
| 159 | 6581-6589 | Chemical | denotes | imatinib | MESH:D000068877 |
| 160 | 6209-6229 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
| 161 | 6637-6645 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 167 | 6903-6911 | Species | denotes | patients | Tax:9606 |
| 168 | 6844-6863 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
| 169 | 6865-6873 | Chemical | denotes | imatinib | MESH:D000068877 |
| 170 | 6879-6890 | Chemical | denotes | baricitinib | MESH:C000596027 |
| 171 | 6894-6902 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 59-68 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
| T2 | 575-580 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
| T3 | 624-648 | Phenotype | denotes | chronic myeloid leukemia | http://purl.obolibrary.org/obo/HP_0005506 |
| T4 | 653-684 | Phenotype | denotes | gastrointestinal stromal tumors | http://purl.obolibrary.org/obo/HP_0100723 |
| T5 | 1005-1014 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
| T6 | 1239-1244 | Phenotype | denotes | fever | http://purl.obolibrary.org/obo/HP_0001945 |
| T7 | 1258-1268 | Phenotype | denotes | arthralgia | http://purl.obolibrary.org/obo/HP_0002829 |
| T8 | 1270-1277 | Phenotype | denotes | malaise | http://purl.obolibrary.org/obo/HP_0012378 |
| T9 | 1282-1287 | Phenotype | denotes | cough | http://purl.obolibrary.org/obo/HP_0012735 |
| T10 | 1496-1504 | Phenotype | denotes | wheezing | http://purl.obolibrary.org/obo/HP_0030828 |
| T11 | 1713-1722 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
| T12 | 2783-2788 | Phenotype | denotes | fever | http://purl.obolibrary.org/obo/HP_0001945 |
| T13 | 3608-3613 | Phenotype | denotes | fever | http://purl.obolibrary.org/obo/HP_0001945 |
| T14 | 3694-3713 | Phenotype | denotes | pulmonary opacities | http://purl.obolibrary.org/obo/HP_0031457 |
| T15 | 4053-4072 | Phenotype | denotes | pulmonary opacities | http://purl.obolibrary.org/obo/HP_0031457 |
| T16 | 4810-4816 | Phenotype | denotes | sepsis | http://purl.obolibrary.org/obo/HP_0100806 |
| T17 | 4821-4838 | Phenotype | denotes | acute lung injury | http://www.orpha.net/ORDO/Orphanet_178320 |
| T18 | 4897-4912 | Phenotype | denotes | pulmonary edema | http://purl.obolibrary.org/obo/HP_0100598 |
| T19 | 5085-5090 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 535-551 | http://purl.obolibrary.org/obo/GO_0033673 | denotes | kinase inhibitor |
| T2 | 1430-1439 | http://purl.obolibrary.org/obo/GO_0007585 | denotes | breathing |
| T3 | 4533-4539 | http://purl.obolibrary.org/obo/GO_0040007 | denotes | growth |
| T4 | 5091-5099 | http://purl.obolibrary.org/obo/GO_0070265 | denotes | necrosis |
| T5 | 5091-5099 | http://purl.obolibrary.org/obo/GO_0019835 | denotes | necrosis |
| T6 | 5091-5099 | http://purl.obolibrary.org/obo/GO_0008219 | denotes | necrosis |
| T7 | 5091-5099 | http://purl.obolibrary.org/obo/GO_0001906 | denotes | necrosis |
| T8 | 5202-5222 | http://purl.obolibrary.org/obo/GO_0000981 | denotes | transcription factor |
| T9 | 5202-5215 | http://purl.obolibrary.org/obo/GO_0006351 | denotes | transcription |
| T10 | 5448-5463 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
| T11 | 5861-5872 | http://purl.obolibrary.org/obo/GO_0140253 | denotes | cell fusion |
| T12 | 5861-5872 | http://purl.obolibrary.org/obo/GO_0045026 | denotes | cell fusion |
| T13 | 5861-5872 | http://purl.obolibrary.org/obo/GO_0000768 | denotes | cell fusion |
| T14 | 5861-5872 | http://purl.obolibrary.org/obo/GO_0000747 | denotes | cell fusion |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-22 | Sentence | denotes | Imatinib for COVID-19: |
| T2 | 23-36 | Sentence | denotes | A case report |
| T3 | 38-329 | Sentence | denotes | Since first cases of pneumonia of unknown etiology were reported on December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global health issue and its related disease (COVID-19) was finally declared a pandemic by World Health Organization on March 2020 [1]. |
| T4 | 330-511 | Sentence | denotes | To date, there is no evidence that consistently supports any treatment for COVID-19 patients, so identifying new therapeutic options seems crucial in the management of this disease. |
| T5 | 512-685 | Sentence | denotes | Imatinib is a tyrosine kinase inhibitor with a well-known anti-tumor activity against several cancers including chronic myeloid leukemia and gastrointestinal stromal tumors. |
| T6 | 686-862 | Sentence | denotes | According to previously published data, this drug has also shown antiviral, immunomodulatory and endothelium-protective properties which may be potentially helpful in COVID-19. |
| T7 | 863-958 | Sentence | denotes | In fact, imatinib has been pointed out as an unexplored treatment for SARS-CoV-2 infection [2]. |
| T8 | 959-1150 | Sentence | denotes | We report the case of a patient with COVID-19 pneumonia who received imatinib due to clinical deterioration despite dual therapy with hydroxychloroquine (HCQ) and lopinavir/ritonavir (LPV/r). |
| T9 | 1151-1288 | Sentence | denotes | On March 12, a 38-year-old woman was admitted to our department with a 6-day history of fever up to 39 °C, arthralgia, malaise and cough. |
| T10 | 1289-1357 | Sentence | denotes | Her blood pressure, heart rate and respiratory rate were all normal. |
| T11 | 1358-1452 | Sentence | denotes | Her temperature was 37.1 °C and oxygen saturation was 96% while she was breathing ambient air. |
| T12 | 1453-1527 | Sentence | denotes | Physical examination only revealed minimal wheezing on chest auscultation. |
| T13 | 1528-1680 | Sentence | denotes | Laboratory results showed a mild elevation of C-reactive protein (CRP) and lactate dehydrogenase (LDH) levels, and a normal lymphocyte count (Table 1 ). |
| T14 | 1681-1723 | Sentence | denotes | Chest X-ray confirmed bilateral pneumonia. |
| T15 | 1724-1936 | Sentence | denotes | Polymerase chain reaction test for SARS-CoV-2 in nasopharyngeal swab was positive, so treatment with HCQ and LPV/r, as well as empiric therapy with ceftriaxone, was initiated in accordance with hospital protocol. |
| T16 | 1937-1966 | Sentence | denotes | Table 1 - Laboratory results. |
| T17 | 1967-2164 | Sentence | denotes | Variable Day 6 of symptoms Day 10 of symptoms Day 13 of symptoms(day 2 of imatinib) Day 14 of symptoms(day 3 of imatinib) Day 16 of symptoms(day 5 of imatinib and discharge) 20 days after discharge |
| T18 | 2165-2209 | Sentence | denotes | CRP, mg/dL 4.79⁎ 21.00⁎ – 25.04⁎ 7.52⁎ 0.57⁎ |
| T19 | 2210-2256 | Sentence | denotes | Procalcitonin, ng/mL – 0.1 0.09 0.06 0.05 0.01 |
| T20 | 2257-2295 | Sentence | denotes | LDH, IU/L 338⁎ 532⁎ 318⁎ 306⁎ 326⁎ 222 |
| T21 | 2296-2346 | Sentence | denotes | Venous lactate, mmol/L 1.0 3.2⁎ 2.7⁎ 2.5⁎ 1.6⁎ 1.1 |
| T22 | 2347-2404 | Sentence | denotes | White-cell count, × 109/L 7.09 8.48 10.19 9.67 7.61 10.25 |
| T23 | 2405-2462 | Sentence | denotes | Neutrophil count, × 109/L 5.44 6.76 8.29⁎ 7.92⁎ 5.56 6.07 |
| T24 | 2463-2519 | Sentence | denotes | Lymphocyte count, × 109/L 1.17 1.31 1.09 0.84† 1.35 3.14 |
| T25 | 2520-2558 | Sentence | denotes | D-dimer, ng/mL – 580⁎ 760⁎ 1129⁎ – 449 |
| T26 | 2559-2613 | Sentence | denotes | CRP = C-reactive protein; LDH = Lactate dehydrogenase. |
| T27 | 2614-2656 | Sentence | denotes | ⁎ The value was above the reference range. |
| T28 | 2657-2699 | Sentence | denotes | † The value was below the reference range. |
| T29 | 2700-2880 | Sentence | denotes | The patient reported initial improvement; however, on March 15 (day 9 of symptoms) fever recurred and supplemental oxygen by nasal cannula at a rate of 3 l per minute was required. |
| T30 | 2881-2993 | Sentence | denotes | Furthermore, both an increase in CRP levels (Table 1) and radiological deterioration were observed (Fig. 1 , a). |
| T31 | 2994-3386 | Sentence | denotes | These clinical changes suggested that the disease was progressing to an early phase of a hyperinflammatory state despite treatment with HCQ and LPV/r; thus, after assessing the safety profile of imatinib [3] and reviewing previous publications about its antiviral and immunomodulatory properties, we considered that this drug may have potentially beneficial effects in such clinical scenario. |
| T32 | 3387-3586 | Sentence | denotes | Hence, informed consent was obtained and imatinib (400 mg once daily) was added on day 12 of symptoms, while ceftriaxone was interrupted since there was no evidence of concurrent bacterial infection. |
| T33 | 3587-3728 | Sentence | denotes | Three days later the fever disappeared, supplemental oxygen was discontinued and radiological stability of pulmonary opacities was confirmed. |
| T34 | 3729-3940 | Sentence | denotes | Moreover, improvement in laboratory parameters was observed on day 5 of imatinib so it was stopped and the patient was subsequently discharged on day 16 of symptoms after also completing 9 days of HCQ and LPV/r. |
| T35 | 3941-4108 | Sentence | denotes | She remained asymptomatic on April 11 (20 days after discharge), her blood tests were then normal (Table 1) and pulmonary opacities had almost disappeared (Fig. 1, b). |
| T36 | 4109-4382 | Sentence | denotes | Fig. 1 a Portable chest X-ray showing radiological deterioration with bilateral patchy opacities (March 17, day 11 of symptoms). b Marked improvement of opacities in posteroanterior chest radiograph (April 11, day 20 after discharge and day 36 after the onset of symptoms). |
| T37 | 4383-4716 | Sentence | denotes | Although developed targeting the oncogenic fusion protein BCR-ABL, imatinib is able to inhibit other tyrosine kinases such as c-KIT, platelet-derived growth factor receptor and Abelson kinases (ABL) type 1 and 2 [4]; therefore, it has been postulated that the biological activity of this drug is not restricted to anticancer effects. |
| T38 | 4717-4792 | Sentence | denotes | In this regard, immunomodulatory properties of imatinib have been reported. |
| T39 | 4793-5119 | Sentence | denotes | Murine models of sepsis and acute lung injury have suggested a protective role of this drug by reducing pulmonary edema, preventing histological damage and improving endothelial barrier dysfunction, probably through attenuation of proinflammatory cytokine release including interleukin-6 and tumor necrosis factor-alpha [4,5]. |
| T40 | 5120-5329 | Sentence | denotes | These effects over inflammatory activation might be mediated by the inhibition of transcription factor NF-κB according to previous evidence from both animal models and studies with human cells [[4], [5], [6]]. |
| T41 | 5330-5483 | Sentence | denotes | Since NF-κB represents a key element in several inflammatory pathways [7], imatinib could be helpful to modulate host immune response against SARS-CoV-2. |
| T42 | 5484-5591 | Sentence | denotes | This is particularly noteworthy given that hyperinflammation plays a central role in severe COVID-19 [3,8]. |
| T43 | 5592-5804 | Sentence | denotes | In addition, imatinib has shown in vitro antiviral activity against severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses [9], which are phylogenetically related to SARS-CoV-2 [10]. |
| T44 | 5805-5960 | Sentence | denotes | In this sense, ABL2 appears to be involved in the virus-cell fusion process, so its blockage could modulate the entry of coronaviruses into host cells [9]. |
| T45 | 5961-6155 | Sentence | denotes | These data also suggest that imatinib might be useful in early stages of SARS-CoV-2 infection, although further research is needed to ascertain the antiviral properties of this drug in COVID-19. |
| T46 | 6156-6265 | Sentence | denotes | To our knowledge, this is the first reported case of SARS-CoV-2 infection successfully treated with imatinib. |
| T47 | 6266-6500 | Sentence | denotes | However, elucidating the relevance of any therapeutic intervention from a single case report is always controversial since clinical outcomes may be influenced by some confounding factors such as the concomitant use of other therapies. |
| T48 | 6501-6646 | Sentence | denotes | Nevertheless, taking into account all the above mentioned data, we believe that imatinib should be considered a potential treatment for COVID-19. |
| T49 | 6648-6655 | Sentence | denotes | Funding |
| T50 | 6656-6689 | Sentence | denotes | No external funding was received. |
| T51 | 6691-6724 | Sentence | denotes | Declaration of Competing Interest |
| T52 | 6725-6912 | Sentence | denotes | David Bernal-Bello is the principal investigator of a non-sponsored randomized trial assessing the therapeutic role of lopinavir/ritonavir, imatinib, and baricitinib in COVID-19 patients. |
| T53 | 6913-6975 | Sentence | denotes | The rest of the authors are sub-investigators in this project. |
| T54 | 6976-7025 | Sentence | denotes | All authors declare no other competing interests. |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 13-21 | SP_7 | denotes | COVID-19 |
| T2 | 121-133 | SP_7 | denotes | severe acute |
| T3 | 134-145 | SP_7;UBERON:0001004 | denotes | respiratory |
| T4 | 146-168 | SP_7 | denotes | syndrome coronavirus 2 |
| T5 | 170-180 | SP_7 | denotes | SARS-CoV-2 |
| T6 | 240-248 | SP_7 | denotes | COVID-19 |
| T7 | 405-413 | SP_7 | denotes | COVID-19 |
| T8 | 542-551 | CHEBI:38637;CHEBI:38637 | denotes | inhibitor |
| T9 | 632-639 | CL:0000763 | denotes | myeloid |
| T10 | 653-677 | UBERON:0003929 | denotes | gastrointestinal stromal |
| T11 | 731-735 | CHEBI:23888;CHEBI:23888 | denotes | drug |
| T12 | 783-794 | UBERON:0001986 | denotes | endothelium |
| T13 | 853-861 | SP_7 | denotes | COVID-19 |
| T14 | 872-880 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T15 | 933-943 | SP_7 | denotes | SARS-CoV-2 |
| T16 | 996-1004 | SP_7 | denotes | COVID-19 |
| T17 | 1028-1036 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T18 | 1093-1111 | CHEBI:5801;CHEBI:5801;DG_20 | denotes | hydroxychloroquine |
| T19 | 1122-1131 | DG_23 | denotes | lopinavir |
| T20 | 1132-1141 | DG_30 | denotes | ritonavir |
| T21 | 1293-1298 | UBERON:0000178 | denotes | blood |
| T22 | 1309-1314 | UBERON:0000948 | denotes | heart |
| T23 | 1324-1335 | UBERON:0001004 | denotes | respiratory |
| T24 | 1508-1513 | UBERON:0001443 | denotes | chest |
| T25 | 1574-1592 | PR:000005897 | denotes | C-reactive protein |
| T26 | 1594-1597 | PR:000005897 | denotes | CRP |
| T27 | 1603-1610 | CHEBI:24996;CHEBI:24996 | denotes | lactate |
| T28 | 1652-1662 | CL:0000542 | denotes | lymphocyte |
| T29 | 1759-1769 | SP_7 | denotes | SARS-CoV-2 |
| T30 | 1773-1787 | UBERON:0001728 | denotes | nasopharyngeal |
| T31 | 1872-1883 | CHEBI:29007;CHEBI:29007 | denotes | ceftriaxone |
| T32 | 2041-2049 | CHEBI:14434;CHEBI:14434 | denotes | imatinib |
| T33 | 2079-2087 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T34 | 2117-2125 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T35 | 2565-2583 | PR:000005897 | denotes | C-reactive protein |
| T37 | 2825-2830 | UBERON:0000004 | denotes | nasal |
| T38 | 3189-3197 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T39 | 3315-3319 | CHEBI:23888;CHEBI:23888 | denotes | drug |
| T40 | 3428-3436 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T41 | 3496-3507 | CHEBI:29007;CHEBI:29007 | denotes | ceftriaxone |
| T42 | 3566-3575 | NCBITaxon:2 | denotes | bacterial |
| T43 | 3694-3703 | UBERON:0002048 | denotes | pulmonary |
| T44 | 3801-3809 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T45 | 4010-4015 | UBERON:0000178 | denotes | blood |
| T46 | 4053-4062 | UBERON:0002048 | denotes | pulmonary |
| T47 | 4127-4132 | UBERON:0001443 | denotes | chest |
| T48 | 4291-4296 | UBERON:0001443 | denotes | chest |
| T51 | 4441-4448 | PR:000044437 | denotes | BCR-ABL |
| T52 | 4450-4458 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T53 | 4511-4514 | PR:000002065 | denotes | KIT |
| T54 | 4516-4524 | CL:0000233 | denotes | platelet |
| T55 | 4577-4580 | PR:000003582 | denotes | ABL |
| T56 | 4671-4675 | CHEBI:23888;CHEBI:23888 | denotes | drug |
| T57 | 4764-4772 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T58 | 4793-4799 | NCBITaxon:39107 | denotes | Murine |
| T59 | 4827-4831 | UBERON:0002048 | denotes | lung |
| T60 | 4880-4884 | CHEBI:23888;CHEBI:23888 | denotes | drug |
| T61 | 4897-4906 | UBERON:0002048 | denotes | pulmonary |
| T62 | 4959-4970 | UBERON:0001986 | denotes | endothelial |
| T63 | 5067-5080 | PR:000001393 | denotes | interleukin-6 |
| T64 | 5085-5112 | PR:000000134 | denotes | tumor necrosis factor-alpha |
| T65 | 5223-5225 | GO:0005883 | denotes | NF |
| T66 | 5270-5276 | NCBITaxon:33208 | denotes | animal |
| T67 | 5301-5306 | SP_6;NCBITaxon:9606 | denotes | human |
| T68 | 5336-5338 | GO:0005883 | denotes | NF |
| T69 | 5405-5413 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T70 | 5434-5442 | GO:0065007 | denotes | modulate |
| T71 | 5443-5447 | GO:0006955 | denotes | host |
| T72 | 5448-5454 | UBERON:0002405;GO:0006955 | denotes | immune |
| T73 | 5455-5463 | GO:0006955 | denotes | response |
| T74 | 5472-5482 | SP_7 | denotes | SARS-CoV-2 |
| T75 | 5576-5584 | SP_7 | denotes | COVID-19 |
| T76 | 5605-5613 | CHEBI:14434;CHEBI:14434 | denotes | imatinib |
| T77 | 5673-5684 | UBERON:0001004 | denotes | respiratory |
| T78 | 5710-5721 | UBERON:0001004 | denotes | respiratory |
| T79 | 5731-5744 | NCBITaxon:11118 | denotes | coronaviruses |
| T80 | 5788-5798 | SP_7 | denotes | SARS-CoV-2 |
| T81 | 5820-5824 | PR:000003583 | denotes | ABL2 |
| T82 | 5855-5860 | NCBITaxon:10239 | denotes | virus |
| T83 | 5861-5872 | GO:0061025 | denotes | cell fusion |
| T84 | 5904-5912 | GO:0065007 | denotes | modulate |
| T85 | 5926-5939 | NCBITaxon:11118 | denotes | coronaviruses |
| T86 | 5990-5998 | CHEBI:14434;CHEBI:14434 | denotes | imatinib |
| T87 | 6034-6044 | SP_7 | denotes | SARS-CoV-2 |
| T88 | 6138-6142 | CHEBI:23888;CHEBI:23888 | denotes | drug |
| T89 | 6146-6154 | SP_7 | denotes | COVID-19 |
| T90 | 6209-6219 | SP_7 | denotes | SARS-CoV-2 |
| T91 | 6256-6264 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T92 | 6581-6589 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T93 | 6637-6645 | SP_7 | denotes | COVID-19 |
| T94 | 6844-6853 | DG_23 | denotes | lopinavir |
| T95 | 6854-6863 | DG_30 | denotes | ritonavir |
| T96 | 6865-6873 | CHEBI:14434;CHEBI:14434 | denotes | imatinib |
| T97 | 6879-6890 | DG_41 | denotes | baricitinib |
| T98 | 6894-6902 | SP_7 | denotes | COVID-19 |
| T28190 | 13-21 | SP_7 | denotes | COVID-19 |
| T24374 | 121-133 | SP_7 | denotes | severe acute |
| T33932 | 134-145 | SP_7;UBERON:0001004 | denotes | respiratory |
| T56060 | 146-168 | SP_7 | denotes | syndrome coronavirus 2 |
| T26460 | 170-180 | SP_7 | denotes | SARS-CoV-2 |
| T26060 | 240-248 | SP_7 | denotes | COVID-19 |
| T27789 | 405-413 | SP_7 | denotes | COVID-19 |
| T76138 | 542-551 | CHEBI:38637;CHEBI:38637 | denotes | inhibitor |
| T3230 | 632-639 | CL:0000763 | denotes | myeloid |
| T40836 | 653-677 | UBERON:0003929 | denotes | gastrointestinal stromal |
| T26513 | 731-735 | CHEBI:23888;CHEBI:23888 | denotes | drug |
| T58114 | 783-794 | UBERON:0001986 | denotes | endothelium |
| T53288 | 853-861 | SP_7 | denotes | COVID-19 |
| T30388 | 872-880 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T2688 | 933-943 | SP_7 | denotes | SARS-CoV-2 |
| T35262 | 996-1004 | SP_7 | denotes | COVID-19 |
| T96047 | 1028-1036 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T20501 | 1093-1111 | CHEBI:5801;CHEBI:5801;DG_20 | denotes | hydroxychloroquine |
| T65802 | 1122-1131 | DG_23 | denotes | lopinavir |
| T69496 | 1132-1141 | DG_30 | denotes | ritonavir |
| T60602 | 1293-1298 | UBERON:0000178 | denotes | blood |
| T2899 | 1309-1314 | UBERON:0000948 | denotes | heart |
| T59609 | 1324-1335 | UBERON:0001004 | denotes | respiratory |
| T50907 | 1508-1513 | UBERON:0001443 | denotes | chest |
| T83820 | 1574-1592 | PR:000005897 | denotes | C-reactive protein |
| T92864 | 1594-1597 | PR:000005897 | denotes | CRP |
| T18754 | 1603-1610 | CHEBI:24996;CHEBI:24996 | denotes | lactate |
| T30315 | 1652-1662 | CL:0000542 | denotes | lymphocyte |
| T73244 | 1759-1769 | SP_7 | denotes | SARS-CoV-2 |
| T27173 | 1773-1787 | UBERON:0001728 | denotes | nasopharyngeal |
| T15380 | 1872-1883 | CHEBI:29007;CHEBI:29007 | denotes | ceftriaxone |
| T53094 | 2041-2049 | CHEBI:14434;CHEBI:14434 | denotes | imatinib |
| T18528 | 2079-2087 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T84378 | 2117-2125 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T90530 | 2565-2583 | PR:000005897 | denotes | C-reactive protein |
| T73943 | 2825-2830 | UBERON:0000004 | denotes | nasal |
| T67666 | 3189-3197 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T83555 | 3315-3319 | CHEBI:23888;CHEBI:23888 | denotes | drug |
| T32599 | 3428-3436 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T58104 | 3496-3507 | CHEBI:29007;CHEBI:29007 | denotes | ceftriaxone |
| T6628 | 3566-3575 | NCBITaxon:2 | denotes | bacterial |
| T74081 | 3694-3703 | UBERON:0002048 | denotes | pulmonary |
| T62264 | 3801-3809 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T47136 | 4010-4015 | UBERON:0000178 | denotes | blood |
| T65080 | 4053-4062 | UBERON:0002048 | denotes | pulmonary |
| T64685 | 4127-4132 | UBERON:0001443 | denotes | chest |
| T35076 | 4291-4296 | UBERON:0001443 | denotes | chest |
| T22209 | 4441-4448 | PR:000044437 | denotes | BCR-ABL |
| T79261 | 4450-4458 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T9446 | 4511-4514 | PR:000002065 | denotes | KIT |
| T51677 | 4516-4524 | CL:0000233 | denotes | platelet |
| T32254 | 4577-4580 | PR:000003582 | denotes | ABL |
| T17766 | 4671-4675 | CHEBI:23888;CHEBI:23888 | denotes | drug |
| T78113 | 4764-4772 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T87073 | 4793-4799 | NCBITaxon:39107 | denotes | Murine |
| T98969 | 4827-4831 | UBERON:0002048 | denotes | lung |
| T45000 | 4880-4884 | CHEBI:23888;CHEBI:23888 | denotes | drug |
| T91193 | 4897-4906 | UBERON:0002048 | denotes | pulmonary |
| T72793 | 4959-4970 | UBERON:0001986 | denotes | endothelial |
| T90859 | 5067-5080 | PR:000001393 | denotes | interleukin-6 |
| T79792 | 5085-5112 | PR:000000134 | denotes | tumor necrosis factor-alpha |
| T26493 | 5223-5225 | GO:0005883 | denotes | NF |
| T65412 | 5270-5276 | NCBITaxon:33208 | denotes | animal |
| T8786 | 5301-5306 | SP_6;NCBITaxon:9606 | denotes | human |
| T63433 | 5336-5338 | GO:0005883 | denotes | NF |
| T57349 | 5405-5413 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T48360 | 5434-5442 | GO:0065007 | denotes | modulate |
| T59414 | 5443-5447 | GO:0006955 | denotes | host |
| T66468 | 5448-5454 | UBERON:0002405;GO:0006955 | denotes | immune |
| T87096 | 5455-5463 | GO:0006955 | denotes | response |
| T74991 | 5472-5482 | SP_7 | denotes | SARS-CoV-2 |
| T32706 | 5576-5584 | SP_7 | denotes | COVID-19 |
| T45081 | 5605-5613 | CHEBI:14434;CHEBI:14434 | denotes | imatinib |
| T88775 | 5673-5684 | UBERON:0001004 | denotes | respiratory |
| T61507 | 5710-5721 | UBERON:0001004 | denotes | respiratory |
| T25185 | 5731-5744 | NCBITaxon:11118 | denotes | coronaviruses |
| T11544 | 5788-5798 | SP_7 | denotes | SARS-CoV-2 |
| T8102 | 5820-5824 | PR:000003583 | denotes | ABL2 |
| T86755 | 5855-5860 | NCBITaxon:10239 | denotes | virus |
| T99959 | 5861-5872 | GO:0061025 | denotes | cell fusion |
| T94733 | 5904-5912 | GO:0065007 | denotes | modulate |
| T61456 | 5926-5939 | NCBITaxon:11118 | denotes | coronaviruses |
| T8366 | 5990-5998 | CHEBI:14434;CHEBI:14434 | denotes | imatinib |
| T88154 | 6034-6044 | SP_7 | denotes | SARS-CoV-2 |
| T36497 | 6138-6142 | CHEBI:23888;CHEBI:23888 | denotes | drug |
| T63516 | 6146-6154 | SP_7 | denotes | COVID-19 |
| T9771 | 6209-6219 | SP_7 | denotes | SARS-CoV-2 |
| T25132 | 6256-6264 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T75604 | 6581-6589 | CHEBI:45783;CHEBI:45783 | denotes | imatinib |
| T47222 | 6637-6645 | SP_7 | denotes | COVID-19 |
| T99569 | 6844-6853 | DG_23 | denotes | lopinavir |
| T38180 | 6854-6863 | DG_30 | denotes | ritonavir |
| T67623 | 6865-6873 | CHEBI:14434;CHEBI:14434 | denotes | imatinib |
| T63693 | 6879-6890 | DG_41 | denotes | baricitinib |
| T80737 | 6894-6902 | SP_7 | denotes | COVID-19 |